我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
隶属于 qilu pharmaceutical group
相关临床试验
218
100 进行中
药物批准
44
批准总数
监管机构
3
监管机构数
成立时间
1992
进行中（未招募）
26
11.9%
已完成
38
17.4%
Enrolling By Invitation
1
0.5%
尚未招募
73
33.5%
招募中
54
24.8%
终止
Unknown
25
11.5%
FDA
Food and Drug Administration
40
CANADA
Health Canada
2
PHILIPPINES
Philippines FDA
- DelveInsight's 2025 pipeline analysis reveals over 10 companies developing more than 10 therapeutic candidates for bone metastasis treatment across various clinical stages. - Mabwell's MW032, a denosumab biosimilar targeting RANKL, has advanced to Phase III trials for bone metastases from solid tumors, representing the most advanced pipeline candidate. - AlaMab Therapeutics' ALMB-0168, a first-in-class monoclonal antibody targeting Cx43 protein, has received FDA orphan drug designation for osteosarcoma treatment. - Exelixis initiated a Phase II combination study of cabozantinib plus nivolumab for advanced castration-resistant prostate cancer in November 2025.
